A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI
Status:
Completed
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of concomitant ramucirumab (IMC-1121B) on
the pharmacokinetics of irinotecan and its metabolite SN-38 when coadministered with folinic
acid and 5-fluorouracil, in participants with advanced malignant solid tumors resistant to
standard therapy or for which no standard therapy is available.